Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose ampicillin-sulbactam with or without nebulized amikacin for ventilator-associated pneumonia caused by resistant Acinetobacter
IRCT20240529061949N1Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in ventilator-associated pneumonia (VAP) comparing Ampicillin-sulbactam plus nebulized amikacin with Ampicillin-sulbactam alone (2 arms). Primary endpoints: Improvement in oxygenation, Reduction in lung secretions and 2 more. Started Jun 2024; status: completed.
02
Drugs
ampicillin + sulbactamamikacin
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on IRCT20240529061949N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240529061949N1.